权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

基本信息

批准号：
10514630
负责人：
Maurizio Del Poeta
金额：
--
依托单位：
NORTHPORT VA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-10-01 至 2025-09-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514630
关键词：
Acquired Immunodeficiency Syndrome Adrenal Cortex Hormones Animal Model Antifungal Agents Antifungal Therapy Aspergillus fumigatus Autoimmune Diseases Award Biological Assay Brain CD4 Positive T Lymphocytes Candida albicans Cell Count Cells Ceramides Cessation of life Clinic Clinical Collaborations Communicable Diseases Communities Containment Cryptococcal Meningitis Cryptococcosis Cryptococcus Cryptococcus neoformans Dependence Development Disease Drug Design Drug Formulations Drug resistance Educational process of instructing Effectiveness Ensure Environment Enzymes Exposure to Faculty Fungal Vaccines General Population Glucosylceramides Goals Granuloma Growth HIV Hand Host Defense Immune Evasion Immune system Immunity Immunocompromised Host Industry Infection Injections Inositol Integration Host Factors Intervention Investigation Knowledge Laboratories Lipids Lung Malignant Neoplasms Mediating Medical Medical center Molecular Morbidity - disease rate Mycoses Organ Transplantation Organism Pathogenesis Pathogenicity Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Physicians Population Postdoctoral Fellow Predisposition Preventive Process Research Research Personnel Resistance SPHK1 enzyme Scientist Services Source South Carolina Specificity Sphingolipids Sphingomyelins Spinal Cord Structure Students Substance abuse problem Symptoms Technology Testing The science of Mycology Therapeutic Therapeutic immunosuppression Toxic effect Toxicology Training Universities Veterans Virulence Work career chemotherapy cross reactivity design experience fungus high throughput screening immunoregulation inhibitor interest microbial microorganism interaction military service mortality multiple sclerosis treatment novel novel therapeutic intervention novel therapeutics opportunistic pathogen patient population research and development small molecule sphingomyelin synthase sphingosine 1-phosphate therapeutically effective

项目摘要

ABSTRACT I am an Infectious Diseases physician-scientist with over 28 years of experience in medical mycology. During my career, I have been working in the clinic and at the bench, teaching and training many students, post-docs and junior faculty at Duke University, the Medical University of South Carolina, and now at Stony Brook University and at the Northport VA Medical Center. My overall career goal is to bring a new antifungal in the clinic, and I am closer than ever with MicroRid Technologies Inc., a start-up company I co-founded for the research and development of new antifungal drugs. My laboratory pioneered the studies on lipid-mediated infectious diseases. My lab and my co-workers reached such a high visibility in this field that we are continuously contacted for consultant work by investigators from all over the world for lipid analysis in their favorite organisms. My studies have mostly focused on fungal infections, particularly invasive fungal infections, because they are on the rise in our Veterans and in our non-Veterans populations. As we live longer thanks to many benefits of chemo- and immunosuppressive-therapies and organ transplantations, we are also facing a rise of invasive fungal infectious diseases. Current antifungals are either fungistatic, toxic, with narrow spectrum of activity or they become resistant. New treatment strategies are needed. In addition to develop a new class of antifungal agents, the studies in my laboratory are also crucial to the understanding of the host mechanisms required for fungal containment versus fungal dissemination and disease. For these studies, I partnered with many collaborators at the VA medical centers, at various Universities, and at the industry setting, establishing fruitful and successful collaborations. The VA RCS award will allow our group to continue this great work and will provide stability to fulfill the current goals and to start new research directions. The RCS Award will also allow me to broaden my collaborative research even further, particularly with the VA physicians involved in the MVP, enhancing my research clinical enterprise, and to continue my service to the scientific community at the VA and beyond.

摘要